Emory University’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Emory University’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-23,333	Closed	-$1.41M	–	22
2015 Q2	$1.41M	Buy	+23,333	New	+$1.54M	1.9%	18

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Emory University's ONCE Position: Q3 2015 in Review

Emory University sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2015, closing a stake of 23,333 shares — an estimated $1.41M sold.

Emory University first reported a position in ONCE in Q2 2015 and held it in 1 quarter. The position peaked at $1.41M in Q2 2015. 90 funds tracked by Wall St. Rank hold ONCE as of Q3 2015.

Emory University reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
Emory University sold 23,333 Spark Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $1.41M.
Emory University first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
Emory University's Spark Therapeutics, Inc. Common Stock position peaked at $1.41M in Q2 2015.
90 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Emory University's 13F filing for Q3 2015, filed 16 Nov 2015.